About HizentraInitiating HizentraAssistance and SupportIgIQ Resource CenterReimbursementCSL Behring Assurance ProgramSHARE Nurse Training and ExamInfusion Support CenterProfessional ResourcesFrequently Asked QuestionsRequest More InformationImportant Safety Information

IgIQ Resource Center

IgIQ is a comprehensive support network for healthcare providers and people who depend on CSL Behring's immunoglobulin (Ig) therapies.

IgIQ gathers many Ig resources under one roof, making it easier for you to get the support you need with a single phone call.

Our friendly and knowledgeable staff can help answer many of your Ig-related questions, provide educational materials, and assist you with a number of issues, including:

  • Insurance verification
  • Coding (including ICD-9-CM codes) and billing
  • General nonmedical product information

To initiate the insurance verification process, please complete the Prescription Referral Form and fax back to the IgIQ Resource Center at
1-866-720-4373.

For additional details—and to get the guidance and support you need—call the IgIQ Resource Center hotline at 1-877-355-IGIQ (1-877-355-4447), Monday through Friday, 8 AM to 8 PM ET.

Verifying Coverage

The IgIQ Resource Center can help you with all types of insurance matters, including coverage, verification, and appeals. However, if you'd like to conduct your own insurance research, it may be helpful to consider the following:

  1. Who is the in-network home infusion provider or specialty pharmacy?
  2. What is the durable medical equipment benefit for the infusion pump?
  3. Is the medication covered? (If you are planning to buy and bill the medication, ask the insurance company specifically about coverage).
  4. Is there a Pharmacy Benefit Manager (PBM) with this plan? If so, verify that the medication is covered through the pharmacy benefits, and that the medication can be obtained through mail order.
  5. Is there a prior authorization required? If so, ask if there is a specific form that needs to be submitted.

Financial questions?

These frequently asked questions can help you learn more about billing and financial assistance for your patients.

Find answers

Support for you and your patients

Find a variety of professional resources, useful links, and clinical publications about Hizentra.

View resources

Important Safety Information

Immune Globulin Subcutaneous (Human), Hizentra®, is indicated as replacement therapy for patients with primary humoral immunodeficiency (PI), age 2 and older. This includes but is not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin preparations or components of Hizentra, such as polysorbate 80. Because it contains the stabilizer L-proline, Hizentra is contraindicated in patients with hyperprolinemia. Hizentra is also contraindicated in patients with immunoglobulin A deficiency who have antibodies against IgA and a history of hypersensitivity.

Hizentra should be administered subcutaneously only. Do not administer intravenously.

IgA-deficient patients with anti-IgA antibodies may be at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions with administration of Hizentra. If hypersensitivity occurs or anaphylactic reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Hizentra is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common drug-related adverse reactions (observed in 5% or more of study subjects receiving Hizentra) were local reactions (ie, swelling, redness, heat, pain, and itching at the injection site), headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, rash, pruritis, vomiting, upper abdominal pain, pain, and migraine.

Monitor patients for thrombotic events and aseptic meningitis (AMS), which have been reported with SCIg. Also look forreactions reported to occur with IVIg treatment that might also occur with Hizentra, including renal dysfunction/failure, hemolysis, and transfusion-related acute lung injury (TRALI).

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. It can also lead to misinterpretation of serologic testing.

Please see full prescribing information for Hizentra.